Synonyms: BA 3021
Ozuriftamab vedotin (BA 3021) is an antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity.
CAS No. 2460400-11-5
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Ozuriftamab vedotin (BA 3021) is an antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity.
|
|---|
| CAS No. | 2460400-11-5 |
|---|---|
| ADC antiody | Ozuriftamab |
| ADC cytotoxin | MMAE |
| Formulation | 1xPBS |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT05271604 | COMPLETED | Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck; Recurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Cancer; Metastatic Squamous Cell Carcinoma of the Head and Neck | BioAtla, Inc. | 2022-12-13 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2025-09-26)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.